Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Triheptanoin - Ultragenyx Pharmaceutical

X
Drug Profile

Triheptanoin - Ultragenyx Pharmaceutical

Alternative Names: C7 fatty acid; C7 oil; Dojolvi; Glycerol triheptanoate; Glyceryl triheptanoate; UX-007

Latest Information Update: 07 Nov 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baylor Research Institute
  • Developer Ultragenyx Pharmaceutical
  • Class Esters; Small molecules; Triglycerides
  • Mechanism of Action Triglyceride replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type II; Lipid metabolism disorders; De Vivo disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lipid metabolism disorders
  • Phase II Glycogen storage disease; Glycogen storage disease type V; Hemiplegia; Huntington's disease; Rett syndrome
  • Phase I/II Amyotrophic lateral sclerosis
  • No development reported Glycogen storage disease type I
  • Discontinued De Vivo disease

Most Recent Events

  • 05 Nov 2024 Ultragenyx Pharmaceutical announces intention to submit NDA to PMDA for Lipid metabolism disorders in mid-2025
  • 05 Nov 2024 Ultragenyx Pharmaceutical receives positive finalized assessment report with agreement to file for Conditional Early Approval (CEA) from the PMDA for triheptanoin in lipid metabolism disorders prior to November 2024
  • 31 Dec 2023 Ultragenyx Pharmaceutical has patent protection for triheptanoin in USA, Australia, Brazil, Canada, Israel, Korea, Malaysia, and Taiwan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top